Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
Dogwood Therapeutics (Nasdaq: DWTX), a clinical-stage biopharmaceutical company formerly known as Virios Therapeutics, has announced it will release its Q3 2024 financial results on Thursday, November 7, 2024, before market open. The company will host a webcast and conference call at 8:30 a.m. ET on the same day, featuring management discussion of results and a corporate update. Investors can access the live call by dialing 888-506-0062 (domestic) or 973-528-0011 (international) using access code 838895, or view the webcast through the company's website under the Investors section.
Dogwood Therapeutics (Nasdaq: DWTX), una società biofarmaceutica in fase clinica precedentemente nota come Virios Therapeutics, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024, prima dell'apertura del mercato. La società organizzerà un webcast e una conferenza telefonica alle 8:30 ET dello stesso giorno, durante i quali ci sarà una discussione della direzione sui risultati e un aggiornamento aziendale. Gli investitori possono accedere alla chiamata in diretta componendo il numero 888-506-0062 (nazionale) o 973-528-0011 (internazionale) utilizzando il codice di accesso 838895, oppure possono visualizzare il webcast attraverso il sito web della società nella sezione Investitori.
Dogwood Therapeutics (Nasdaq: DWTX), una compañía biofarmacéutica en etapa clínica anteriormente conocida como Virios Therapeutics, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, antes de la apertura del mercado. La compañía llevará a cabo un webcast y una llamada de conferencia a las 8:30 a.m. ET el mismo día, que incluirá una discusión de la gestión sobre los resultados y una actualización corporativa. Los inversores pueden acceder a la llamada en vivo marcando el 888-506-0062 (nacional) o el 973-528-0011 (internacional) utilizando el código de acceso 838895, o ver el webcast a través del sitio web de la compañía en la sección de Inversores.
도그우드 테라퓨틱스 (Nasdaq: DWTX), 이전에 비리오스 테라퓨틱스라는 이름으로 알려진 임상 단계의 생명공학 회사가 2024년 3분기 재무 결과를 2024년 11월 7일 목요일 시장 개장 전에 발표할 것이라고 밝혔습니다. 회사는 같은 날 오전 8시 30분(동부 시간)에 경영진의 결과 논의와 기업 업데이트를 포함한 웹캐스트와 컨퍼런스 콜을 개최합니다. 투자자는 888-506-0062(국내) 또는 973-528-0011(국제)으로 접속 코드 838895를 사용하여 생방송 전화를 통해 접속할 수 있으며, 회사 웹사이트의 투자자 섹션을 통해 웹캐스트를 시청할 수 있습니다.
Dogwood Therapeutics (Nasdaq: DWTX), une entreprise biopharmaceutique en phase clinique autrefois connue sous le nom de Virios Therapeutics, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le jeudi 7 novembre 2024, avant l'ouverture du marché. L'entreprise organisera un webinaire et une conférence téléphonique le même jour à 8 h 30, heure de l'Est, proposant une discussion sur les résultats par la direction et une mise à jour de l'entreprise. Les investisseurs peuvent accéder à l'appel en direct en composant le 888-506-0062 (national) ou le 973-528-0011 (international) en utilisant le code d'accès 838895, ou regarder le webinaire sur le site de l'entreprise dans la section Investisseurs.
Dogwood Therapeutics (Nasdaq: DWTX), ein biopharmazeutisches Unternehmen in klinischer Phase, das zuvor als Virios Therapeutics bekannt war, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 am Donnerstag, den 7. November 2024, vor Handelsbeginn veröffentlichen wird. Das Unternehmen veranstaltet am selben Tag um 8:30 Uhr ET einen Webcast und eine Telefonkonferenz, in der das Management die Ergebnisse und ein Unternehmensupdate diskutiert. Investoren können die Live-Schaltung unter der Nummer 888-506-0062 ( national) oder 973-528-0011 (international) mit dem Zugangscode 838895 erreichen oder den Webcast über die Website des Unternehmens im Bereich Investoren ansehen.
- None.
- None.
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report third quarter 2024 financial results on Thursday, November 7, 2024 before the open of the financial markets. Management will also host a webcast and conference call on November 7, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
The live and archived webcast of the call may be accessed on the Dogwood Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Dogwood Therapeutics Conference Call" using the access code: 838895.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms that include a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on lead development candidate, Halneuron® which is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain. Halneuron® treatment has demonstrated pain reduction of both general cancer related pain and chemotherapy-induced neuropathic pain (“CINP”). Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent, celecoxib, for the treatment of illnesses believed to be related to reactivation of previously dormant herpes viruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). Top-line data from an ongoing IMC-2 Phase 2 LC study are expected in mid-November 2024. IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. For more information, please visit www.dwtx.com.
Follow Dogwood Therapeutics
Email Alerts: https://ir.dwtx.com/resources/email-alerts
LinkedIn: https://www.linkedin.com/company/dogwoodther/
Twitter: https://twitter.com/dogwoodther
Facebook: https://www.facebook.com/dogwoodther
Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Contact:
IR@dwtx.com
FAQ
When will Dogwood Therapeutics (DWTX) report Q3 2024 earnings?
How can I access Dogwood Therapeutics (DWTX) Q3 2024 earnings call?
What time is Dogwood Therapeutics (DWTX) Q3 2024 earnings call?
